Neuro-oncology
From the Journals
Bacteremic sepsis in ALL linked to later cognitive issues
Patients who survive acute lymphoblastic leukemia still may face cognitive impairment later in life because of sepsis during treatment.
From the Journals
Immunotherapies extend survival for melanoma patients with brain metastases
Patients with melanoma brain metastases receiving first-line checkpoint blockade immunotherapy had a 91% increase in 4-year survival.
From the Journals
Recombinant poliovirus appears safe, active as recurrent glioblastoma treatment
The survival data in a phase 1 study of 61 patients showed a plateau, with a 36-month survival rate of 21%, compared with 4% for a historical...
Conference Coverage
What Is the Prevalence of Sleep Disorders in Neurologic Populations?
LOS ANGELES—About one-third of neurologic patients has a high risk of obstructive sleep apnea (OSA), and approximately one-...
FDA/CDC
FDA: Gadolinium retention prompts new GBCA class warning, safety measures
Gadolinium-based contrast agents used for MRI will now carry a warning regarding potential retention in the bodies and brains of treated patients...
FDA/CDC
FDA: Gadolinium retention prompts new GBCA class warning, safety measures
Gadolinium-based contrast agents used for MRI will now carry a warning regarding potential retention in the bodies and brains of treated patients...
Conference Coverage
What Are the Long-Term Neurologic Complications of Childhood Cancer?
KANSAS CITY, MO—As cancer treatment advances, the prevalence of childhood cancer survivors increases; as a result, physicians see more neurologic...
Literature Review
Genomic Profiling May Improve Pediatric Brain Tumor Treatment
Genomic profiling of 282 pediatric gliomas detected genetic alterations in 96% of the cases, according to research published online ahead of print...
FDA/CDC
FDA approves biosimilar to bevacizumab
Bevacizumab-awwb is approved for the treatment of adults with certain colorectal, lung, brain, kidney, and cervical cancers.
Literature Review
Pembrolizumab and Nivolumab May Cause Neurologic Events
Approximately 3% of patients developed adverse neurologic events within 12 months of receiving nivolumab or pembrolizumab, according to the...
From the Journals
Pembrolizumab, nivolumab linked to 3% rate of neurologic events
Ten of 347 patients (2.9%) receiving nivolumab or pembrolizumab developed subacute neurologic immune-related adverse events, typically...